| scholarly article | Q13442814 |
| P50 | author | Shu Chen | Q42886084 |
| Xinglong Wang | Q47502785 | ||
| P2093 | author name string | Xiongwei Zhu | |
| Amy L Wilson-Delfosse | |||
| Payal N Gandhi | |||
| P2860 | cites work | The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity | Q36154267 |
| Molecular pathophysiology of Parkinson's disease | Q36196507 | ||
| Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin | Q36728266 | ||
| Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein | Q40199182 | ||
| Parkin stabilizes microtubules through strong binding mediated by three independent domains. | Q40452676 | ||
| Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease | Q40672194 | ||
| DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity | Q41848995 | ||
| Filaments of Lewy bodies contain insoluble cytoskeletal elements | Q41863606 | ||
| The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor | Q46649179 | ||
| Rotenone inhibition of spindle microtubule assembly in mammalian cells. | Q47829132 | ||
| DAP-kinase-mediated morphological changes are localization dependent and involve myosin-II phosphorylation | Q47997547 | ||
| Mechanisms of MPTP toxicity | Q48456918 | ||
| Mutant dynactin in motor neuron disease. | Q52603971 | ||
| Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodie | Q55486342 | ||
| LRRK2 mutations in Parkinson disease | Q57983290 | ||
| Lrrk2 pathogenic substitutions in Parkinson's disease | Q57983291 | ||
| Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes | Q59508508 | ||
| Epidemiology of Parkinson's disease | Q64859305 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| Tubulin seeds alpha-synuclein fibril formation | Q24291881 | ||
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| Identification of potential protein interactors of Lrrk2 | Q24301415 | ||
| Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin | Q24302415 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase | Q27860571 | ||
| Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta | Q28199148 | ||
| Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra | Q28257569 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation | Q28572388 | ||
| Small GTP-binding proteins | Q29547372 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| Dominant effects of tubulin overexpression in Saccharomyces cerevisiae | Q30450404 | ||
| Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. | Q33226010 | ||
| Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data | Q33226682 | ||
| Identification of genes related to Parkinson's disease using expressed sequence tags | Q33268719 | ||
| A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium | Q34090804 | ||
| Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. | Q34132759 | ||
| Roc, a Ras/GTPase domain in complex proteins | Q34280792 | ||
| The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases | Q34443373 | ||
| The identification of pats1, a novel gene locus required for cytokinesis in Dictyostelium discoideum | Q34450548 | ||
| Disruption of cellular transport: a common cause of neurodegeneration? | Q35172288 | ||
| The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor | Q35447263 | ||
| The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia | Q35974169 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1711-1720 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Journal of Neuroscience Research | Q6295654 |
| P1476 | title | The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules | |
| P478 | volume | 86 |
| Q34454883 | A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. |
| Q24310126 | A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation |
| Q38697548 | A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway |
| Q24305448 | ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2 |
| Q33985278 | Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution |
| Q24298093 | Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers |
| Q36325683 | Cellular effects of LRRK2 mutations |
| Q35545939 | Coordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5. |
| Q33565399 | Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect |
| Q37249125 | Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. |
| Q37119983 | Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases |
| Q36491685 | Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? |
| Q41117800 | Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects |
| Q33593798 | ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease |
| Q37330540 | Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. |
| Q64060780 | Functional Segments on Intrinsically Disordered Regions in Disease-Related Proteins |
| Q38814476 | GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q38044437 | Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? |
| Q24293070 | Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice |
| Q54988601 | Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population. |
| Q24653530 | Intrabody and Parkinson's disease |
| Q54781213 | Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. |
| Q36477677 | Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity |
| Q42873469 | LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. |
| Q38620229 | LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? |
| Q35688632 | LRRK2 Parkinson disease mutations enhance its microtubule association. |
| Q37890433 | LRRK2 Parkinson's disease: from animal models to cellular mechanisms |
| Q40899192 | LRRK2 Promotes Tau Accumulation, Aggregation and Release. |
| Q54976406 | LRRK2 and mitochondria: Recent advances and current views. |
| Q38198207 | LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? |
| Q38044441 | LRRK2 and vesicle trafficking |
| Q24306239 | LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations |
| Q34280111 | LRRK2 function on actin and microtubule dynamics in Parkinson disease |
| Q37608626 | LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles |
| Q33999270 | LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding |
| Q24317760 | LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25 |
| Q24323196 | LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity |
| Q38218398 | LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis |
| Q36888947 | LRRK2: an éminence grise of Wnt-mediated neurogenesis? |
| Q37635000 | LRRK2: cause, risk, and mechanism |
| Q42416558 | Leucine-Rich Repeat Kinase 1 Regulates Autophagy through Turning On TBC1D2-Dependent Rab7 Inactivation |
| Q33812599 | Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease |
| Q38977031 | Leucine-rich repeat kinase 2 and Parkinson's disease |
| Q37829776 | Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? |
| Q34259058 | Leucine-rich repeat kinase 2 for beginners: six key questions. |
| Q37225356 | Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions |
| Q24303851 | Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export |
| Q33594388 | Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. |
| Q34005501 | Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys |
| Q36325784 | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. |
| Q37996364 | Mechanisms of LRRK2-mediated neurodegeneration. |
| Q34292484 | Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts |
| Q35799109 | Mitochondrial dysfunction in genetic animal models of Parkinson's disease |
| Q35799128 | Mitochondrial quality control and dynamics in Parkinson's disease |
| Q34986076 | Models for LRRK2-Linked Parkinsonism |
| Q34086842 | Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration |
| Q26781649 | Neurodegeneration and microtubule dynamics: death by a thousand cuts |
| Q34637362 | Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo |
| Q37856642 | On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies |
| Q40116327 | Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. |
| Q36042047 | Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function |
| Q42324120 | Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies. |
| Q53387936 | Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. |
| Q37599929 | Pathway for Parkinson disease |
| Q47270899 | Potential for therapeutic targeting of AKAP signaling complexes in nervous system disorders |
| Q37325908 | RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis |
| Q60951726 | Roco Proteins and the Parkinson's Disease-Associated LRRK2 |
| Q60921580 | Roco Proteins: GTPases with a Baroque Structure and Mechanism |
| Q34300430 | Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease |
| Q35771011 | Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning |
| Q39119334 | Sec16 in conventional and unconventional exocytosis: Working at the interface of membrane traffic and secretory autophagy? |
| Q52312842 | Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. |
| Q38160939 | Targeting leucine-rich repeat kinase 2 in Parkinson's disease |
| Q38044433 | The GTPase function of LRRK2. |
| Q42509261 | The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway |
| Q48157527 | The LRRK2 R1628P variant plays a protective role in Han Chinese population with Alzheimer's disease |
| Q35679501 | The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. |
| Q50048940 | The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity |
| Q46428440 | The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm |
| Q33521241 | The WD40 domain is required for LRRK2 neurotoxicity |
| Q37371868 | The function of ROCO proteins in health and disease. |
| Q26991986 | The regulation and deregulation of Wnt signaling by PARK genes in health and disease |
| Q36325701 | The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease |
| Q37775037 | Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy |
| Q37395783 | Update on the functional biology of Lrrk2. |
| Q37313530 | Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. |
| Q35932488 | α-synuclein, LRRK2 and their interplay in Parkinson's disease. |
Search more.